WO2006047227A1 - Compositions et methodes de traitement de tissus hypertrophiques - Google Patents

Compositions et methodes de traitement de tissus hypertrophiques Download PDF

Info

Publication number
WO2006047227A1
WO2006047227A1 PCT/US2005/037771 US2005037771W WO2006047227A1 WO 2006047227 A1 WO2006047227 A1 WO 2006047227A1 US 2005037771 W US2005037771 W US 2005037771W WO 2006047227 A1 WO2006047227 A1 WO 2006047227A1
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
composition
delivery vehicle
regulatory element
nucleic acid
Prior art date
Application number
PCT/US2005/037771
Other languages
English (en)
Inventor
Daniel G. Anderson
Robert S. Langer
Robert F. Padera, Jr.
Weiden Peng
Janet A. Sawicki
Original Assignee
Massachusetts Institute Of Technology
Lankenau Institute For Medical Research
Brigham & Women's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2005/007001 external-priority patent/WO2005089123A2/fr
Application filed by Massachusetts Institute Of Technology, Lankenau Institute For Medical Research, Brigham & Women's Hospital filed Critical Massachusetts Institute Of Technology
Publication of WO2006047227A1 publication Critical patent/WO2006047227A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Abstract

La présente invention concerne des compositions et des méthodes de traitement d'états pathologiques et de maladies associées a une croissance excessive ou inappropriée de tissus non cancéreux. Dans certains modes de réalisation, on utilise des compositions ou des méthodes pour le traitement d'une hyperplasie bénigne de la prostate. Dans d'autres modes de réalisation, la composition comprend un véhicule à sélectivité tissulaire. Dans d'autres modes de réalisation encore, les compositions renferment un vecteur d'expression codant pour un polypeptides cytotoxique, l'expression du polypeptide cytotoxique étant commandée par un élément régulateur spécifique de la prostate. Enfin, l'invention peut concerner un vecteur d'expression dans lequel l'expression d'une recombinase est commandée par un élément régulateur spécifique de la prostate et où l'expression du polypeptide cytotoxique ne peut avoir lieu qu'en présence d'un événement de recombinaison induit par la recombinase.
PCT/US2005/037771 2004-10-21 2005-10-21 Compositions et methodes de traitement de tissus hypertrophiques WO2006047227A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US62088604P 2004-10-21 2004-10-21
US60/620,886 2004-10-21
USPCT/US2005/007001 2005-03-04
US11/074,323 2005-03-04
PCT/US2005/007001 WO2005089123A2 (fr) 2004-03-04 2005-03-04 Traitement anticancereux a base d'adn
US11/074,323 US20050215507A1 (en) 2004-03-04 2005-03-04 Therapeutic anti-cancer DNA

Publications (1)

Publication Number Publication Date
WO2006047227A1 true WO2006047227A1 (fr) 2006-05-04

Family

ID=36228114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/037771 WO2006047227A1 (fr) 2004-10-21 2005-10-21 Compositions et methodes de traitement de tissus hypertrophiques

Country Status (1)

Country Link
WO (1) WO2006047227A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
WO2013018096A1 (fr) * 2011-08-03 2013-02-07 Ramot At Tel-Aviv University Ltd. Utilisation d'une intégrase pour l'expression génique ciblée
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580859A (en) * 1989-03-21 1996-12-03 Vical Incorporated Delivery of exogenous DNA sequences in a mammal
US5712384A (en) * 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580859A (en) * 1989-03-21 1996-12-03 Vical Incorporated Delivery of exogenous DNA sequences in a mammal
US5712384A (en) * 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
US8795286B2 (en) 2009-09-25 2014-08-05 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
WO2013018096A1 (fr) * 2011-08-03 2013-02-07 Ramot At Tel-Aviv University Ltd. Utilisation d'une intégrase pour l'expression génique ciblée
US9816077B2 (en) 2011-08-03 2017-11-14 Ramot At Tel-Aviv University Ltd. Use of integrase for targeted gene expression

Similar Documents

Publication Publication Date Title
US20060228404A1 (en) Compositions and methods for treatment of hypertrophic tissues
Burke et al. Extracellular barriers to in vivo PEI and PEGylated PEI polyplex-mediated gene delivery to the liver
Zou et al. Systemic linear polyethylenimine (L‐PEI)‐mediated gene delivery in the mouse
Ko et al. Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide
Miao et al. Co-administration of dual-targeting nanoparticles with penetration enhancement peptide for antiglioblastoma therapy
Dirisala et al. Optimized rod length of polyplex micelles for maximizing transfection efficiency and their performance in systemic gene therapy against stroma-rich pancreatic tumors
EP1915449B1 (fr) Conjugues siarn-polymeres hydrophiles pour l'administration intracellulaire de petits arn interferents et methode associee
US8969543B2 (en) SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
Xue et al. Delivery of microRNA-1 inhibitor by dendrimer-based nanovector: An early targeting therapy for myocardial infarction in mice
Swingle et al. Ionizable lipid nanoparticles for in vivo mRNA delivery to the placenta during pregnancy
Kowalski et al. Anti-VCAM-1 SAINT-O-Somes enable endothelial-specific delivery of siRNA and downregulation of inflammatory genes in activated endothelium in vivo
Gujrati et al. Targeted dual pH‐sensitive lipid ECO/siRNA self‐assembly nanoparticles facilitate in vivo cytosolic sieIF4E delivery and overcome paclitaxel resistance in breast cancer therapy
JPH10503469A (ja) 緻密にした核酸および細胞へのデリバリ
Keogh et al. High efficiency reporter gene transfection of vascular tissue in vitro and in vivo using a cationic lipid–DNA complex
Yu et al. Efficient siRNA transfer to knockdown a placenta specific lncRNA using RGD-modified nano-liposome: A new preeclampsia-like mouse model
An et al. Locally Trapping the C‐C Chemokine Receptor Type 7 by Gene Delivery Nanoparticle Inhibits Lymphatic Metastasis Prior to Tumor Resection
Zeng et al. PEGylated cationic vectors containing a protease-sensitive peptide as a miRNA delivery system for treating breast cancer
JP3684371B2 (ja) 内皮細胞増殖阻害剤およびその使用法
Wan et al. In Vivo Delivery of siRNAs Targeting EGFR and BRD4 Expression by Peptide-Modified Redox Responsive PEG–PEI Nanoparticles for the Treatment of Triple-Negative Breast Cancer
Wang et al. Polyethylene glycol–poly (ε-benzyloxycarbonyl-L-lysine)-conjugated VEGF siRNA for antiangiogenic gene therapy in hepatocellular carcinoma
Rodier et al. Linear polyethylenimine-DNA nanoconstruct for corneal gene delivery
WO2006047227A1 (fr) Compositions et methodes de traitement de tissus hypertrophiques
Mao et al. Critical involvement of lysyl oxidase in seizure-induced neuronal damage through ERK-Alox5-dependent ferroptosis and its therapeutic implications
Liu et al. A programmable hierarchical-responsive nanoCRISPR elicits robust activation of endogenous target to treat cancer
PT1079843E (pt) Utilização dos inibidores do receptor de integrina 1 1 e dos inibidores de fct- 1 no tratamento de doenças do rim

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV LY MD MG MK MN MW MX MZ NA NG NO NZ OM PG PH PL PT RO RU SC SD SG SK SL SM SY TJ TM TN TR TT TZ UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IS IT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05815444

Country of ref document: EP

Kind code of ref document: A1